ChemicalBook
Chinese Japanese Germany Korea

Deferasirox

Overview Preparation Pharmacological effects Pharmacokinetics Side effects Uses Precautions
Deferasirox
Deferasirox structure
CAS No.
201530-41-8
Chemical Name:
Deferasirox
Synonyms
20kg;Exjade;ICL-670;CGP-72670;deferasirox;Deferisirox;Deferasirox D8;Deferasirox, >=99%;Deferasirox(Exjade);Decitabine USP RC C
CBNumber:
CB7855359
Molecular Formula:
C21H15N3O4
Formula Weight:
373.3615
MOL File:
201530-41-8.mol

Deferasirox Properties

Melting point:
260-2620C
storage temp. 
-20°C Freezer
pka
pKa1 4.57, pKa2 8.71, pKa3 10.56 (Nick); Also reported in H2O/DMSO (CDMSO = 0.20) as pKa1 4.61, pKa2 10.12, pKa3 12.08 (Steinhauser)

SAFETY

Deferasirox price More Price(4)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 16753 Deferasirox ≥98% 201530-41-8 1mg $29 2018-11-13 Buy
Cayman Chemical 16753 Deferasirox ≥98% 201530-41-8 5mg $99 2018-11-13 Buy
Cayman Chemical 16753 Deferasirox ≥98% 201530-41-8 10mg $189 2018-11-13 Buy
Cayman Chemical 16753 Deferasirox ≥98% 201530-41-8 25mg $435 2018-11-13 Buy

Deferasirox Chemical Properties,Uses,Production

Overview

Deferasirox: chemical name 4-[3,5-bis (2-hydroxyphenyl)-1,2,4-triazol-1-yl] benzoic acid, is a kind of iron chelator products studied and developed by the Novartis company (Swiss). It was the first routinely used oral iron agent approved by US FDA, allowed to be applied for the treatment of iron overloading caused by blood transfusion in patients (older than 2 years old) of chronic anemia. In Europe, it is recommended as the first-line treatment drug for patients older than 6-year-old who are suffering blood iron overload patients. In China, it is currently subject to clinical research; Ⅱ, Ⅲ clinical trials and pharmacokinetic studies have all shown that it has excellent safety and tolerability, and can significantly reduce the heart, liver iron load, easy to be accepted by the patient. At the same time, it also has pharmacological properties of antifungal (such as Mucor which can grow in iron-ricking environment), anti-cell proliferation, anti-malaria, antioxidant stress injury and anti-cytotoxicity induced apoptosis; it can be used for the treatment of hemochromatosis, delayed skin porphyria and other diseases.

Preparation

Take salicylic acid as raw material; it undergoes chlorination through thionyl chloride to obtain salicylic acid chloride. Salicylic acid chloride and salicylic acid amide are placed under the condition of high temperature and vacuum distillation instead of ordinary reflux method to obtain intermediates, further evaporating into large amount of low-boiling and by-products through high temperature vacuum distillation, making the mass fraction of the intermediate be increased from 88.7% to 97.5%. Finally, after the removal of hydrochloric acid, the carboxyl-phenylhydrazine hydrochloride is subject to cyclization with the intermediate to prepare the product of deferasirox, reducing the steps of desalting and solvents steaming-off in the post-reaction treatment while reducing the amount of anhydrous ethanol as well so that the operation becomes simpler.
1. Preparation of salicylic acid chloride (Compound 1)
Salicylic acid (13.8 g, 0.1 mol), 10 drops of anhydrous pyridine and 10 mL of thionyl chloride were added to the reaction flask. The mixture was subject to stirred reaction at room temperature for 30 min and slowly heated to 70 °C with stirring until almost no hydrogen chloride gas was released. Further heat to 80 °C and stir for 3 h. Residual thionyl chloride was distilled off under reduced pressure to give a pale yellow liquid which was cooled to precipitate crystals and used directly in the next reaction.
2. Preparation of the 2-(2-hydroxyphenyl)-[1, 3] benzoxazinone (Compound 2)
Salicylic acid (13.7 g, 0.1 mol) and the compound 1 obtained from the last step of reaction are added to the reaction flask equipped with a distillation apparatus and heated to 180 ° C. The reaction mixture was reacted with distillation under reduced pressure at the same time for 3 h to remove water from the reaction. 50 mL of absolute ethanol was added under melting to precipitate the solid yellow product. After filtration and recrystallization from anhydrous ethanol, we can obtain 16.8 g of a yellow product with a yield 70.3% and mp 210-213 °C.
3. Preparation of p-carboxyphenylhydrazine hydrochloride (Compound 3)
4-aminobenzoic acid (6.85 g, 0.05 mol) and 10 mL of distilled water were added into a 250 mL three-necked flask. The mixture was stirred to become a paste and added of drop wise of 12.5 mL of concentrated hydrochloric acid at 5 ° C. The solution was cooled to 5 ° C in an ice-salt bath. Upon stirring, slowly add drop wise of a sodium nitrite saturated solution (3.5 g, 0.05 mol of sodium nitrite is dissolved in a small amount of water (8 g)) for diazotization reaction. The reaction temperature is kept below 5 ℃ and further stirred for 30 mins after the completion of dropping.
The diazonium salt solution was then poured into a solution with sodium sulfite (25.2 g, 0.2 mol) dissolved in water (100 mL) pre-cooled to 5 °C. Stir at this temperature for 30 min, and heat to 80 ° C for 1.5 h. The orange-red solution will be changed to yellowish. Cool it to room temperature; slowly add hydrochloric acid for acidification to pH 3 to obtain the p-carboxyphenylhydrazine hydrochloride precipitate. Further apply filtration and drying to get 8.3 g white product with a yield of 88.3%.
4. Preparation of Deferasirox
The compound 3 (3.8 g, 0.02 mol) was adjusted to pH 6 with 30% NaOH, stirred, and stand for layering so that the water layers were separated. The oil layer was p-carboxyphenylhydrazine. The oil layer was placed in a flask; add compound II (5.0 g; 0.02 mol) and reflux for 2 h in anhydrous ethanol (75 mL). Cool, precipitate the crystals; filtrate and rinse with 10 mL of ice ethanol, dry and perform ethanol-water recrystallization, to obtain 6.3 g micro-yellow product with a yield of 84.45%.
synthetic route of Deferasirox
Figure 1 synthetic route of Deferasirox

Pharmacological effects

DFS has antifungal activity (such as Mucor growing in the iron-rich environment), anti-cell proliferation, anti-malaria, anti-oxidative stress injury, anti-cytotoxicity induced apoptosis and other pharmacological effects.
1.  DFS and fungal infection
Iron is a substance that fungi rely on, and plays a very important role in the growth and toxicity of fungi. The antifungal effect of iron chelator may be due to their effect of removal of the iron necessary for fungal growth, so as to achieve the purpose of treatment of fungal infection.
2. DFS and cell proliferation
Iron plays a very important role in the process of cell proliferation. Iron chelators may have anti-proliferative properties, suggesting that iron chelators may be a novel anticancer agent for the treatment of tumors.

Pharmacokinetics

DFS is a tridentate iron chelator that binds ferric ions in a 2: 1 ratio to form complexes that are excreted from the feces, reducing the storage of iron in the body. As DFS persists in plasma, the plasma non-transferring binding iron can be continuously reduced, thus directly eliminating the iron toxicity formed in vivo. The main metabolic pathway of DFS is via glucuronidation for producing metabolites M3 (acylglucuronide) and M6 (2-O-glucuronide).
Administration of large-dose DFS may present some acute adverse reactions, such as gastrointestinal symptoms (15%) and rash (11%). However, patients who finally discontinue the drug treatment due to these symptoms are rare.

Side effects

For patients with renal insufficiency, DFS can lead to increased creatinine levels with 38% of patients getting creatinine levels increased by 33% or more. But DFS-induced creatinine increase will generally not exceed the normal upper limit and there has not yet been progress in renal disease reported. After a reduction in DFS, creatinine levels returned to normal or remained stable in 13% of patients.
<1% of patients can get hearing impairment (hearing loss, hearing reduction) and ocular diseases (lens opacities, cataracts, elevated intraocular pressure and retinopathy), and therefore it is recommended to participate into hearing and visual capability examination (including slit lamp examination and fundus examination)annually before and during the period of iron therapy, once found, it should be considered to disable DFS.
Common side effects of deferasirox in Chinese patients with thalassemia include: rash, abdominal pain, diarrhea, and elevated transaminase level and serum creatinine level; mostly mild with no serious adverse reactions.
Deferasirox can cause renal damage and gastrointestinal bleeding, and therefore it is recommended to detect 2 times of creatine clearance rates before the treatment; detect once per week during the initial stage of treatment, followed by once per month. Gastrointestinal bleeding is a common adverse reaction of this drug that can be fatal in older patients with advanced malignancies or thrombocytopenia, and these patients are unlikely to benefit from the treatment with this drug.
Deferasirox may lead to serious adverse effects of liver failure. The patient must subject to regular monitoring of liver function during the medication process. If there is difficult to explain, persistent or progressive increase on the serum aminotransferase levels, we should adjust the usage or withdraw the drug.

Uses

1. DFS can be used to treat the reversible renal insufficiency caused by Fanconi syndrome.
2. It can be used for the treatment of secondary hemochromatosis.
3. It can be used for the treatment of delayed skin porphyria.
4. It can be used for the treatment of myelodysplastic syndromes.
5. It can be used for the treatment of iron overloading caused by blood transfusion for patients (older than 2 years old) of chronic anemia This information is compiled and edited by Ding Hong of Chemicalbook. (2015-09-18)

Precautions

Patients with allergy to deferasirox are disabled.

Description

Iron overload is a potentially life-threatening cumulative toxicity that occurs frequently in patients who receive multiple blood transfusions for the treatment of certain types of chronic anemias such as thalassemia and sickle-cell disease, as well as for the treatment of myelodysplastic syndromes. Progressive iron overload, if untreated, often causes injury to heart, liver, endocrine organs, joints, and other target cells and tissues. Iron overload is treated by administration of iron chelators, which mobilize the iron deposits into soluble complexes that can be excreted from the body. The current standard of care in iron chelation, deferoxamine (Desferal ?), is effective, but typically requires subcutaneous infusion lasting eight to twelve hours per day, for five to seven days a week for as long as the patient continues to receive blood transfusions. In many patients, the need for transfusion and chelation therapy may be life-long. This has resulted in low patient acceptance of the product. Deferipone is an orally available iron chelator that has been marketed in certain parts of the world; however, it has a short duration of action and may be associated with serious side effects. Deferasirox is an orally active tridentate ligand that binds iron with high affinity in a 2:1 ratio. The recommended dosage is 20 mg/kg of body weight once, daily. Deferasirox is synthesized in two steps starting from salicylamide, by first condensing with salicyloyl chloride to afford 2- (2-hydroxyphenyl)benz[1,3]oxazin-4-one, and subsequent reaction of this intermediate with 4-hydrazinobenzoic acid. Deferasirox is rapidly absorbed following oral administration, reaching peak plasma concentrations at 1.5–4 h. The Cmax and AUC increase approximately linearly with dose after both single administration and under steady-state conditions. Deferasirox is highly protein bound (99%), almost exclusively to serum albumin. It has a volume of distribution at steady state of 14.37±2.69 L, mean elimination half-life ranging from 8 to 16 hours, and oral bioavailability of 70%. Glucuronidation is the main metabolic pathway for deferasirox, with minimal oxidative metabolism by CYP450 enzymes. Deferasirox and metabolites are primarily excreted in the feces via the bile (84% of the dose). Clinical trials involving more than 1000 adults and children demonstrated that deferasirox, at 20–30 mg/kg/day led to maintenance of or reductions in liver iron concentration, an indicator for body iron content in patients receiving blood transfusions. The most frequently reported adverse events were transient in nature and included mild to moderate nausea, vomiting, diarrhea, abdominal pain, and skin rash. In addition, patients treated with deferasirox experienced doserelated increase in serum creatinine at a greater frequency compared with deferoxamine- treated patients (38% vs. 15%, respectively). However, most of the creatinine elevations remained within the normal range. As with deferoxamine injection, deferasirox was associated with a low incidence of ocular and auditory disturbances.

Chemical Properties

White to Off-White Solid

Originator

Novartis (Switzerland)

Uses

Orally active tridentate iron chelator

Uses

Biological Activity Chemical Information Tech Support & FAQs Biological Activity Deferasirox(Exjade) is a rationally-designed oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions

Uses

A tridentate chelator that binds iron with high affinity

Uses

Labeled Deferasirox, intended for use as an internal standard for the quantification of Deferasirox by GC- or LC-mass spectrometry.

Definition

ChEBI: A member of the class of triazoles, deferasirox is 1,2,4-triazole substituted by a 4-carboxyphenyl group at position 1 and by 2-hydroxyphenyl groups at positions 3 and 5. An orally active iron chelator, it is used to manage chronic iron overload in patient receiving long-term blood transfusions.

brand name

Exjade (Novartis).

Deferasirox Preparation Products And Raw materials

Raw materials

Preparation Products


Deferasirox Suppliers

Global( 177)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Capot Chemical Co.,Ltd.
+86 (0)571-855 867 18
+86 (0)571-858 647 95 sales@capotchem.com China 19918 60
Henan DaKen Chemical CO.,LTD.
+86-371-55531817
info@dakenchem.com CHINA 21954 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 20680 55
ATK CHEMICAL COMPANY LIMITED
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 ivan@atkchemical.com CHINA 24196 60
Biochempartner
0086-13720134139
candy@biochempartner.com CHINA 956 58
Shenzhen Nexconn Pharmatechs Ltd
15013857715
admin@nexconn.com CHINA 2560 58
Chemwill Asia Co.,Ltd.
86-21-51086038
86-21-51861608 chemwill_asia@126.com;sales@chemwill.com;chemwill@hotmail.com;chemwill@gmail.com CHINA 24001 58
Hubei Jusheng Technology Co.,Ltd.
86-188-71490254
peter@hubeijusheng.com CHINA 20095 58
QUALITY CONTROL CHEMICALS INC.
(323) 306-3136
(626) 453-0409 orders@qcchemical.com United States 8409 58
career henan chemical co
+86-371-86658258
sales@coreychem.com CHINA 20331 58

View Lastest Price from Deferasirox manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2018-08-01 Deferasirox
201530-41-8
US $2000.00 / KG 1KG 98% 10kg career henan chemical co

201530-41-8(Deferasirox)Related Search:


  • Deferisirox
  • Deferasirox(CGP-72670)
  • 4-[3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid
  • Deferasirox(Exjade)
  • 4-[3,5-bis(2-hydroxyphenyl)
  • 20kg
  • Deferasirox, >=99%
  • Deferasirox D8
  • 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid
  • deferasirox
  • Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-
  • Deferasirox for research
  • -
  • Aromatics
  • Chelating Agents & Ligands
  • Heterocycles
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Pharmaceutical intermediate
  • 530-41-8
  • 140891-02-6
  • C21H15N3O4
  • 4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic Acid
  • CGP-72670
  • Exjade
  • ICL-670
  • Decitabine USP RC C
  • 201530-41-8
  • Exjade, ICL-670, ICL-670A, CGP-72670
  • Chelating agent (iron)
  • Aromatics Compounds
Copyright 2017 © ChemicalBook. All rights reserved